Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1958 2
1961 2
1962 2
1964 2
1965 2
1966 6
1967 5
1968 6
1969 3
1970 10
1971 2
1972 10
1973 2
1974 4
1975 9
1976 11
1977 15
1978 17
1979 15
1980 17
1981 17
1982 22
1983 29
1984 33
1985 53
1986 49
1987 67
1988 60
1989 65
1990 59
1991 63
1992 60
1993 65
1994 55
1995 73
1996 76
1997 72
1998 87
1999 104
2000 94
2001 93
2002 102
2003 131
2004 115
2005 155
2006 158
2007 165
2008 179
2009 183
2010 219
2011 263
2012 270
2013 329
2014 321
2015 301
2016 286
2017 278
2018 241
2019 263
2020 305
2021 356
2022 364
2023 317
2024 314
2025 316
2026 24

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

6,648 results

Results by year

Filters applied: . Clear all
Page 1
Zongertinib in Previously Treated HER2-Mutant Non-Small-Cell Lung Cancer.
Heymach JV, Ruiter G, Ahn MJ, Girard N, Smit EF, Planchard D, Wu YL, Cho BC, Yamamoto N, Sabari JK, Zhao Y, Tu HY, Yoh K, Nadal E, Sadrolhefazi B, Rohrbacher M, von Wangenheim U, Eigenbrod-Giese S, Zugazagoitia J; Beamion LUNG-1 Investigators. Heymach JV, et al. Among authors: yamamoto n. N Engl J Med. 2025 Jun 19;392(23):2321-2333. doi: 10.1056/NEJMoa2503704. Epub 2025 Apr 28. N Engl J Med. 2025. PMID: 40293180 Clinical Trial.
Zongertinib (BI 1810631), an Irreversible HER2 TKI, Spares EGFR Signaling and Improves Therapeutic Response in Preclinical Models and Patients with HER2-Driven Cancers.
Wilding B, Woelflingseder L, Baum A, Chylinski K, Vainorius G, Gibson N, Waizenegger IC, Gerlach D, Augsten M, Spreitzer F, Shirai Y, Ikegami M, Tilandyová S, Scharn D, Pearson MA, Popow J, Obenauf AC, Yamamoto N, Kondo S, Opdam FL, Bruining A, Kohsaka S, Kraut N, Heymach JV, Solca F, Neumüller RA. Wilding B, et al. Among authors: yamamoto n. Cancer Discov. 2025 Jan 13;15(1):119-138. doi: 10.1158/2159-8290.CD-24-0306. Cancer Discov. 2025. PMID: 39248702 Free PMC article.
First-in-human study of AMG 193, an MTA-cooperative PRMT5 inhibitor, in patients with MTAP-deleted solid tumors: results from phase I dose exploration.
Rodon J, Prenen H, Sacher A, Villalona-Calero M, Penel N, El Helali A, Rottey S, Yamamoto N, Ghiringhelli F, Goebeler ME, Doi T, Postel-Vinay S, Lin CC, Liu C, Chuang CH, Keyvanjah K, Eggert T, O'Neil BH. Rodon J, et al. Among authors: yamamoto n. Ann Oncol. 2024 Dec;35(12):1138-1147. doi: 10.1016/j.annonc.2024.08.2339. Epub 2024 Sep 16. Ann Oncol. 2024. PMID: 39293516 Free article. Clinical Trial.
Hypotension after general anaesthesia induction using remimazolam or propofol in geriatric patients undergoing sevoflurane anaesthesia with remifentanil: a single-centre, double-blind, randomised controlled trial.
Takaki R, Yokose M, Mihara T, Saigusa Y, Tanaka H, Yamamoto N, Masui K, Goto T. Takaki R, et al. Among authors: yamamoto n. Br J Anaesth. 2024 Jul;133(1):24-32. doi: 10.1016/j.bja.2024.04.013. Epub 2024 May 22. Br J Anaesth. 2024. PMID: 38777646 Free article. Clinical Trial.
The Japanese Critical Care Nutrition Guideline 2024.
Nakamura K, Yamamoto R, Higashibeppu N, Yoshida M, Tatsumi H, Shimizu Y, Izumino H, Oshima T, Hatakeyama J, Ouchi A, Tsutsumi R, Tsuboi N, Yamamoto N, Nozaki A, Asami S, Takatani Y, Yamada K, Matsuishi Y, Takauji S, Tampo A, Terasaka Y, Sato T, Okamoto S, Sakuramoto H, Miyagi T, Aki K, Ota H, Watanabe T, Nakanishi N, Ohbe H, Narita C, Takeshita J, Sagawa M, Tsunemitsu T, Matsushima S, Kobashi D, Yanagita Y, Watanabe S, Murata H, Taguchi A, Hiramoto T, Ichimaru S, Takeuchi M, Kotani J. Nakamura K, et al. Among authors: yamamoto n. J Intensive Care. 2025 Mar 21;13(1):18. doi: 10.1186/s40560-025-00785-z. J Intensive Care. 2025. PMID: 40119480 Free PMC article. Review.
In reply.
Hayashi M, Yamamoto N, Shiroshita A. Hayashi M, et al. Among authors: yamamoto n. Ann Emerg Med. 2025 Jan;85(1):96-97. doi: 10.1016/j.annemergmed.2024.08.001. Ann Emerg Med. 2025. PMID: 39706612 No abstract available.
Glenoid track revisited.
Itoi E, Yamamoto N, Di Giacomo G, Marcello G. Itoi E, et al. Among authors: yamamoto n. J Shoulder Elbow Surg. 2024 Dec;33(12):2791-2799. doi: 10.1016/j.jse.2024.03.044. Epub 2024 May 10. J Shoulder Elbow Surg. 2024. PMID: 38735636 Review.
HER2-Selective Tyrosine Kinase Inhibitor, Zongertinib (BI 1810631), in Patients With Advanced/Metastatic Solid Tumors With HER2 Alterations: A Phase Ia Dose-Escalation Study.
Heymach JV, Opdam F, Barve M, Tu HY, Wu YL, Berz D, Schröter L, Botilde Y, Sadrolhefazi B, Serra J, Yoh K, Yamamoto N. Heymach JV, et al. Among authors: yamamoto n. J Clin Oncol. 2025 Apr 10;43(11):1337-1347. doi: 10.1200/JCO-24-01727. Epub 2025 Mar 3. J Clin Oncol. 2025. PMID: 40030100 Free PMC article. Clinical Trial.
Durvalumab with etoposide and carboplatin for patients with extensive-stage small cell lung cancer and interstitial lung disease: A multicenter, open-label prospective trial.
Shibaki R, Fujimoto D, Miyauchi E, Tsukita Y, Nakachi I, Arai D, Sakata Y, Shingu N, Shimokawa T, Kijima T, Tamiya M, Kawana S, Hara S, Saito G, Sato Y, Yokoyama T, Sakata S, Taniguchi Y, Hata A, Matsumoto H, Yamaguchi T, Yamamoto N. Shibaki R, et al. Among authors: yamamoto n. Lung Cancer. 2024 Oct;196:107958. doi: 10.1016/j.lungcan.2024.107958. Epub 2024 Sep 19. Lung Cancer. 2024. PMID: 39312871 Clinical Trial.
6,648 results